Active Clinical Trials
Clinical trials are at the heart of our work to bring innovative medicines to people with a particular disease or condition. Learn more about the active studies conducted by Novartis including opportunities to get involved.
- Sort by Sort ascending
- Study title
- Condition
- Phase
- Location
| Study title | Condition | Phase | Location |
|---|---|---|---|
Study of Dose Confirmation and Safety of Crizanlizumab in Pediatric Sickle Cell Disease Patients |
Sickle Cell Disease (SCD) | Phase 2 | Turkey Spain Lebanon Germany United States Belgium Colombia United Kingdom Italy Canada Oman France Brazil View All |
Dabrafenib and/or Trametinib Rollover Study |
Melanoma, Non Small Cell Lung Cancer, Solid Tumor, Rare Cancers, High Grade Glioma | Phase 4 | United States Spain Hungary |
Dose Finding Study of TNO155 in Adult Patients With Advanced Solid Tumors |
Advanced EGFRmutant NonSmallSellLungCancer (NSCLC),KRAS G12-mutant NSCLC,Esophageal SquamousCellCancer (SCC),Head/Neck SCC,Melanoma | Phase 1 | United States Netherlands Spain Japan Italy Korea, Republic of Singapore Taiwan Canada View All |
Study to Allow Patients Previously Participating in a Novartis Sponsored Trial to Continue Receiving Capmatinib Treatment as Single Agent or in Combination With Other Treatments or the Combination Treatment Alone |
Advanced Solid Tumors Which Are cMET-dependent | Phase 2 | United States Germany Belgium Italy Korea, Republic of Singapore View All |
Ribociclib (LEE011) Rollover Study for Continued Access |
Continued Access to Study Treatment(s), Cancers With a Mass, Bulky Tumor, Nodule, Lump, Advanced Cancer, Advanced Solid Tumors, Advanced Solid Malignancies | Phase 2 | Taiwan United States |
Roll-over Study to Allow Access to Certinib (LDK378) for Patients Who Are on Ceritinib Treatment in a Novartis-sponsored Study |
ALK Positive Malignancies | Phase 4 | Brazil China France |
CAR-T Long Term Follow Up (LTFU) Study |
Long Term Safety of Patients Receiving CAR-T in an Eligible Clinical Trial or Managed Access Program | Phase 3 | United States Spain Germany Australia Japan Denmark Belgium Canada Finland United Kingdom Italy Norway France Israel Singapore Taiwan Austria View All |
CINC424A2X01B Rollover Protocol |
Primary Myelofibrosis, Polycythemia Vera, Graft Versus Host Disease, Acute Myeloid Leukemia, Thalassemia | Phase 4 | Japan Italy Korea, Republic of |
Safety and Efficacy of Fingolimod in Pediatric Patients With Multiple Sclerosis |
Multiple Sclerosis | Phase 3 | Serbia Romania Ukraine United Kingdom Spain France United States View All |
The Gilenya Pregnancy Registry |
Multiple Sclerosis | Denmark United Arab Emirates Portugal Netherlands Greece Argentina Switzerland Lebanon Germany Colombia Australia Belgium Slovakia France Romania Hungary United States Italy Ireland Sweden Austria Saudi Arabia Israel Poland Spain Slovenia Mexico Russian Federation United Kingdom Cyprus Czech Republic Brazil Canada Finland View All |